ISLAND PHARMACEUTICALS LTD
ASX: ILA (ISLAND PHA FPO [ILA])
Kemas kini terakhir: 13 jam lalu0.430
0.01 (2.38%)
| Penutupan Terdahulu | 0.420 |
| Jumlah Dagangan | 93,852 |
| Harga / Jualan (P/S) | 411.23 |
| Harga / Buku (P/B) | 9.46 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -1,556.27% |
| EPS Cair (TTM) | -0.030 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -89.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 27.78% |
| Nisbah Semasa (MRQ) | 10.27 |
| Aliran Tunai Operasi (OCF TTM) | -2.89 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -1.71 M |
| Pulangan Atas Aset (ROA TTM) | -65.80% |
| Pulangan Atas Ekuiti (ROE TTM) | -143.22% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (AU) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | ISLAND PHA FPO [ILA] | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.50 |
|
Island Pharmaceuticals Ltd is a drug research and repurposing company focused on developing preventative or therapeutic drugs for viral infections, public health, or biosecurity threats. The company is following a dual development plan for its assets, ISLA-101 and Galidesivir. Its product candidate, ISLA-101, is being repurposed for the prevention and treatment of dengue fever and other mosquito-borne (or vector) borne diseases. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika, and Yellow fever viruses, with unmet medical needs. The company operates in a single segment, being research and development activities in Australia and the United States of America. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 60.56% |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |